VSEEW VSEE HEALTH, INC.

Price Chart

Executive Summary

VSee Health completed a negotiated separation from its wholly-owned subsidiary VSee Lab, selling all equity to co-CEO/Chairman Milton Chen in exchange for his 2,870,069 common shares of VSee Health. Chen resigned as co-CEO and chairman, and Dr. Imoigele Aisiku was appointed sole CEO and chairman. The pro forma financials show the company shedding approximately half its revenue base (VSee Lab contributed ~$7.3M of $14.6M in FY2025 revenue) while also eliminating a significant portion of current liabilities ($4.0M reduction). The transaction effectively deleverages the balance sheet but materially shrinks the operating scale of the remaining entity.

Actionable Insight

Key Facts

• VSee Health sold 100% of VSee Lab to co-founder/co-CEO Milton Chen on May 31, 2026.
• Consideration: Chen transferred his 2,870,069 shares of VSee Health common stock back to the company (treasury stock valued at $545,313).
• Chen resigned as co-CEO and chairman; Dr. Imoigele Aisiku appointed sole CEO and chairman.
• Pro forma FY2025 revenue drops from $14.6M to $7.3M (VSee Lab contributed ~50% of revenue).
• Pro forma current liabilities reduced by ~$4.0M (from $11.8M to $7.8M), including elimination of $1.45M deferred revenue and $2.2M accounts payable.
• Pro forma net loss improves from -$14.7M to -$10.0M for FY2025, and from -$2.6M to -$1.26M for Q1 2026.
• Pro forma cash decreases slightly from $1.35M to $1.24M.
• The transaction is a 'clean break' — VSee Health retains pre-closing liabilities of VSee Lab; Chen assumes post-closing operations.
• No cash changed hands; the deal was a stock-for-stock swap with mutual releases.

Financial Impact

Pro forma FY2025 revenue declines 50% from $14.6M to $7.3M; pro forma net loss improves by ~$4.7M; current liabilities reduced by ~$4.0M. No cash consideration exchanged.

Risk Factors

• Revenue base halved — remaining ~$7.3M pro forma revenue may not be sufficient to achieve profitability or positive cash flow.
• Founder/co-CEO departure creates key-person risk and potential loss of institutional knowledge.
• Cash position of ~$1.24M is thin for a public company with ongoing operating losses (pro forma Q1 2026 net loss of ~$1.26M).
• VSee Health retained pre-closing liabilities of VSee Lab, which could include unknown contingencies.
• Warrant overhang (VSEEW warrants exercisable at $11.50/share) remains outstanding with no current in-the-money value.

Market Snapshot

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

US Market Status

Related Tickers